Articles published by Pathos AI

Pathos AI Enters Collaboration and Co-Exclusive Licensing Agreement to Advance Novel ERα PROTAC for ER+ Breast Cancer into the Clinic

Today 20:00 EDT

From Pathos AI

Via Business Wire

Pathos AI Enters Global Licensing Agreement with Alphamab Oncology on JSKN016, a First-in-Class TROP2/HER3 Bispecific ADC

Today 20:00 EDT

From Pathos AI

Via Business Wire

Pathos AI Acquires Majority Stake in DeuterOncology to Advance Next-Generation MET Inhibitor Identified by Pathos Foundry Platform

May 06, 2026

From Pathos AI

Via GlobeNewswire

Pathos AI Secures $365 Million in Series D Financing to Advance Oncology Drug Development Through AI

May 15, 2025

From Pathos AI

Via GlobeNewswire

Pathos AI Appoints Iker Huerga as Chief Executive Officer to Lead the Next Era of AI-Enabled Drug Development

May 08, 2025

From Pathos AI

Via GlobeNewswire

Pathos AI Doses First Patient in Phase 1b/2a Clinical Trial of Pocenbrodib, a CBP/p300 Inhibitor

March 20, 2025

From Pathos AI

Via GlobeNewswire

Pathos AI Closes $62M Oversubscribed Series C Round of Financing to Accelerate its Platform Approach to Drug Development

October 29, 2024

From Pathos AI

Via GlobeNewswire

Pathos Expands Pipeline With Worldwide License of Phase 2-ready Brain-penetrant, PRMT5 Inhibitor

August 15, 2024

From Pathos AI

Via GlobeNewswire

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.